Inhibrx Biosciences, Inc. (INBX) Stock Price & Analysis
Inhibrx Biosciences, Inc. (INBX) fell 0.89% to USD 121.17 as of September 8, 2026 at 06:58 UTC, according to Nexqual real-time market data.
INBX last closed at USD 121.17; the session ranged USD 120.48–124.19 on volume of 196,513 shares. Market capitalization is —, with a 52-week range of USD 26.19–155.29 (NMS). Source: Nexqual, September 8, 2026 at 06:58 UTC.
Key Statistics (as of September 8, 2026 at 06:58 UTC)
| Price | USD 121.17 |
|---|---|
| Change | ▼ 0.89% (down) |
| Previous Close | USD 121.17 |
| Open | USD 121.17 |
| Day Range | USD 120.48 – 124.19 |
| 52-Week Range | USD 26.19 – 155.29 |
| Volume | 196,513 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (INBX)
Nexqual's technical model rates INBX "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 06:58 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 66.8 (neutral) |
| vs SMA50 | Above (USD 97.19) |
| MACD | 9.07 (positive) |
From Inhibrx Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Overview We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms.
- Our Solution — ozekibart Ozekibart is a tetravalent agonist of DR5 that we designed with our proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis.
- We have engineered ozekibart with our proprietary sdAb modifications to reduce recognition by pre-existing anti-drug antibodies in humans, which can lessen the potential for hyper-clustering and thereby reduce potential hepatotoxicity. 6 ozekibart: Tetravalent DR5 Agonistic Antibody Phase 1/2 Clinical Trial of ozekibart We initiated a Phase 1 clinical trial in the United States in November 2018.
- Intellectual Property We strive to protect the proprietary technology and information commercially or strategically important to our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | USD 11.32 | ▲ 0.8% |
| KYMR | Kymera Therapeutics, Inc. | USD 117.39 | ▼ 1.05% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 14.97 | ▲ 0.2% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 3.99 | ▲ 5.84% |
| NRIX | Nurix Therapeutics, Inc. | USD 26.14 | ▲ 1.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:58 UTC. This page is informational and not investment advice.